Clinical use in COVID-19
Dipyridamole is an inhibitor of phosphodiesterase 3 and 5, thereby it increases intracellular cAMP and/or cGMP in platelets and inhibits platelet aggregation (209). Besides, it has antiviral features against several viruses (210,211). Dipyridamole as an adjunctive therapy was demonstrated to be associated with decreased D-dimer levels in COVID-19 (212).